Xbrane Biopharma Future Growth
Future criteria checks 6/6
Xbrane Biopharma is forecast to grow earnings and revenue by 105.2% and 58.4% per annum respectively. EPS is expected to grow by 119.5% per annum. Return on equity is forecast to be 53.3% in 3 years.
Key information
105.2%
Earnings growth rate
119.5%
EPS growth rate
Biotechs earnings growth | 46.9% |
Revenue growth rate | 58.4% |
Future return on equity | 53.3% |
Analyst coverage | Low |
Last updated | 25 Apr 2024 |
Recent future growth updates
Recent updates
Market Might Still Lack Some Conviction On Xbrane Biopharma AB (publ) (STO:XBRANE) Even After 32% Share Price Boost
Jun 21Is Xbrane Biopharma (STO:XBRANE) In A Good Position To Deliver On Growth Plans?
Jun 04We Think Xbrane Biopharma (STO:XBRANE) Needs To Drive Business Growth Carefully
Nov 05Market Sentiment Around Loss-Making Xbrane Biopharma AB (publ) (STO:XBRANE)
Mar 24Xbrane Biopharma AB (publ) (STO:XBRANE) Insiders Increased Their Holdings
Mar 02Xbrane Biopharma AB (publ)'s (STO:XBRANE) Intrinsic Value Is Potentially 28% Above Its Share Price
Feb 10We Think Xbrane Biopharma (STO:XBRANE) Can Afford To Drive Business Growth
Jan 12What Kind Of Investors Own Most Of Xbrane Biopharma AB (publ) (STO:XBRANE)?
Dec 16Insider Buying: The Xbrane Biopharma AB (publ) (STO:XBRANE) Head of Manufacturing & Supply Chain Just Bought 50% More Shares
Nov 20Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 1,122 | 644 | N/A | N/A | 2 |
12/31/2025 | 680 | 104 | 320 | 329 | 2 |
12/31/2024 | 344 | -186 | -43 | -13 | 2 |
3/31/2024 | 191 | -361 | -465 | -463 | N/A |
12/31/2023 | 239 | -322 | -423 | -407 | N/A |
9/30/2023 | 189 | -285 | -467 | -441 | N/A |
6/30/2023 | 144 | -246 | -427 | -389 | N/A |
3/31/2023 | 112 | -189 | -340 | -296 | N/A |
12/31/2022 | 58 | -169 | -254 | -194 | N/A |
9/30/2022 | 43 | -146 | -216 | -139 | N/A |
6/30/2022 | 32 | -147 | -229 | -127 | N/A |
3/31/2022 | 15 | -172 | -282 | -182 | N/A |
12/31/2021 | 11 | -183 | -297 | -220 | N/A |
9/30/2021 | 8 | -213 | -278 | -227 | N/A |
6/30/2021 | 5 | -219 | -286 | -268 | N/A |
3/31/2021 | 3 | -215 | -160 | -147 | N/A |
12/31/2020 | N/A | -218 | -242 | -238 | N/A |
9/30/2020 | N/A | -222 | -169 | -165 | N/A |
6/30/2020 | N/A | -210 | -146 | -145 | N/A |
3/31/2020 | N/A | -204 | -180 | -179 | N/A |
12/31/2019 | N/A | -188 | -150 | -149 | N/A |
9/30/2019 | 5 | -154 | -118 | -117 | N/A |
6/30/2019 | 7 | -56 | 0 | 2 | N/A |
3/31/2019 | 12 | -40 | 0 | 2 | N/A |
12/31/2018 | 20 | -13 | 45 | 47 | N/A |
9/30/2018 | 25 | 0 | -8 | -4 | N/A |
6/30/2018 | 23 | -69 | -51 | -47 | N/A |
3/31/2018 | 23 | -45 | -40 | -36 | N/A |
12/31/2017 | 21 | -45 | N/A | -37 | N/A |
9/30/2017 | 11 | -35 | N/A | -35 | N/A |
6/30/2017 | 11 | -34 | N/A | -39 | N/A |
3/31/2017 | 6 | -31 | N/A | -41 | N/A |
12/31/2016 | N/A | -28 | N/A | -39 | N/A |
9/30/2016 | 0 | -24 | N/A | -37 | N/A |
6/30/2016 | 0 | -19 | N/A | -27 | N/A |
3/31/2016 | 1 | -16 | N/A | -19 | N/A |
12/31/2015 | 0 | -12 | N/A | -12 | N/A |
9/30/2015 | 2 | -8 | N/A | -5 | N/A |
12/31/2014 | 2 | -3 | N/A | -3 | N/A |
12/31/2013 | 0 | -2 | N/A | N/A | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: XBRANE is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.1%).
Earnings vs Market: XBRANE is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: XBRANE is expected to become profitable in the next 3 years.
Revenue vs Market: XBRANE's revenue (58.4% per year) is forecast to grow faster than the Swedish market (1.1% per year).
High Growth Revenue: XBRANE's revenue (58.4% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: XBRANE's Return on Equity is forecast to be very high in 3 years time (53.3%).